CEO Topic

Exelixis' CEO Topic features periodic commentary on our progress and achievements from our CEO, Michael M. Morrissey, Ph.D. These commentaries are designed to provide additional context around important events such as our quarterly financial results, clinical data presentations, participation in investor conferences, and the initiation and completion of clinical trials. New commentaries are posted periodically and complement the information we provide through our news releases.

With a growing arsenal of targeted agents, Exelixis is taking aim at the key receptors and signaling molecules that are dysregulated in cancer. Where cancer was once classified only at the level of cells and tissues, we now have a better understanding of the genes, proteins, and biochemical pathways that are implicated in various types of cancer. At Exelixis, this knowledge is the foundation of our drug discovery and development strategy.